Guest Francesca L, Guest Paul C
Taunton and Somerset NHS Trust, Musgrove Park Hospital, Taunton, TA1 5DA, UK.
Laboratory of Neuroproteomics, Institute of Biology, University of Campinas, Cidade Universitária Zeferino Vaz, 13083-862, Campinas, Brazil.
Adv Exp Med Biol. 2017;974:363-370. doi: 10.1007/978-3-319-52479-5_35.
This chapter describes how innovations that are driven by proteomic biomarker techniques can facilitate earlier and better treatment of patients who suffer from psychiatric disorders. The application of new micro-fluidic devices along with miniaturized biosensors and transducers will enable the development of handheld point-of-care testing instruments which can analyse a drop of a blood within the time span of a single visit to the doctor's office. It is anticipated that these approaches will incorporate both biochemical and clinical information, resulting in unique profiles for each test subject. These profiles can in turn be used to drive personalized medicine approaches in this devastating disease area. In addition, smartphone applications (apps) for self-monitoring will see increasing use for improved patient outcomes.
本章描述了蛋白质组学生物标志物技术驱动的创新如何促进对精神疾病患者的更早、更有效的治疗。新型微流控设备与小型化生物传感器及换能器的应用，将推动手持式即时检测仪器的开发，这种仪器能够在单次就诊的时间内分析一滴血液。预计这些方法将整合生化和临床信息，为每个测试对象生成独特的概况。这些概况反过来可用于在这个极具破坏性的疾病领域推动个性化医疗方法。此外，用于自我监测的智能手机应用程序将越来越多地被用于改善患者的治疗效果。
